OneCare Biotechnologies is a precision diagnostics company developing cutting-edge tools for the early detection of neuropsychiatric disorders. We combine molecular biology, artificial intelligence, and inclusive data science to build next-generation biomarker platforms that serve the full diversity of human health.
We believe that equitable access to early, accurate diagnosis is fundamental to improving outcomes, and that no community should be left behind in the era of precision medicine. Our mission is to transform how complex disorders are detected and monitored by designing tools that are not only clinically effective but also globally relevant, ethically grounded, and representative of the populations they aim to serve.
Our work spans translational research, clinical validation, and AI model development, with a strong focus on mental health research. We are actively building strategic partnerships across academia, industry, and healthcare systems to accelerate real-world impact.
OneCare is developing blood-based biomarker tools designed to bring greater precision and objectivity to psychiatric care and research.
The OneCare platform integrates molecular analysis and biomarker discovery to identify biological signals associated with psychiatric conditions and treatment response. By translating complex molecular data into clinically relevant insights, our technology aims to support more precise psychiatric care.
Psychiatry remains one of the only medical fields without widely adopted biological tools to support diagnosis and treatment decisions. OneCare Biotechnologies is developing blood-based biomarker platforms designed to uncover molecular signals associated with psychiatric conditions and treatment response.
Our team combines expertise in neuroscience, human genetics, psychiatry, deep learning, and business to develop biological tools that can bring greater precision and objectivity to mental health care.
Dr. Julien Ouellet is a neuroscientist specializing in psychiatry and brain disorders. He holds a PhD in Neuroscience from the Université de Montréal and has authored multiple peer-reviewed publications on psychiatric research. His work focuses on translating advances in neuroscience into practical tools that can improve diagnosis and treatment in mental health.
Murielle M. Akpa is a human geneticist and biotechnology executive with experience in translational research, clinical program management, and scientific operations. She holds a PhD in Human Genetics from McGill University and an Executive MBA from the joint Queen’s–Cornell EMBA Americas program.
Aiken Chung is a biomedical researcher with expertise in molecular biology, data analysis, and multidisciplinary biomedical technologies. With over a decade of research experience spanning academia and industry, his work focuses on integrating computational and biological approaches to advance biomarker discovery and diagnostic innovation.
Dr. Laurent Elkrief is a psychiatrist and clinical researcher specializing in severe mental disorders and computational psychiatry. He completed his medical degree and psychiatric training at the Université de Montréal and conducts research at the CHUM Research Centre. His work focuses on integrating clinical data, genetics, and computational approaches to better understand psychiatric disorders and treatment response.
Stay updated on OneCare’s latest research, partnerships, and milestones.
OneCare Biotechnologies is developing objective blood-based tools to improve diagnosis and decision-making in psychiatry.
© 2025 OneCare Biotechnologies. All rights reserved.
